載入中
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
前收盤價
US$1.27
−US$0.03 · -2.31%
盤中時間採用ET。市場資料可能有所延遲。
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
日內區間
目前US$1.27
52週區間
目前US$1.27
盤中時間採用ET。市場資料可能有所延遲。
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
日內區間
目前US$1.27
52週區間
目前US$1.27
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 4.6萬 USD | — | — | — | 51.9萬 USD |
| 毛利 | −4.6萬 USD | — | — | — | −51.9萬 USD |
| 研究與開發 | 1523.4萬 USD | 1447.8萬 USD | 1585.9萬 USD | 835萬 USD | 1890.3萬 USD |
| 銷售、一般及管理費用 | 788.7萬 USD | 972.6萬 USD | 2221.6萬 USD | 584.3萬 USD | 1704.4萬 USD |
| 營業費用 | 2312.1萬 USD | 2420.4萬 USD | 3807.5萬 USD | 1419.3萬 USD | 3542.8萬 USD |
| 利息收入 | 71.3萬 USD | — | — | — | 12.6萬 USD |
| 利息支出 | 142.2萬 USD | — | 11萬 USD | 13.2萬 USD | 12.6萬 USD |
| 折舊和攤銷 | 4.6萬 USD | 5.8萬 USD | 5.8萬 USD | 5.2萬 USD | 51.9萬 USD |
| 營業利益 | −2312.1萬 USD | −2420.4萬 USD | −3807.5萬 USD | −1419.3萬 USD | −3594.7萬 USD |
| 淨利 | −2956.2萬 USD | −1370萬 USD | −3435.7萬 USD | −782.4萬 USD | −3582.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
